NVITAL is a service laboratory that operates under GLP conditions to perform validated immune assays in support of VRC human and non-human primate vaccine trials. It also performs high throughput screening for monoclonal antibody discovery and immunogen design. NVITAL maintains all sample inventory and assay results in a fully auditable LIMS system that will support all aspects of regulatory scrutiny. This allows NVITAL to provide the VRC with documents necessary to support product regulatory filings.
|Enama, Mary E; Ledgerwood, Julie E; Novik, Laura et al. (2014) Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). PLoS One 9:e91366|
|Ledgerwood, Julie E; Zephir, Kathryn; Hu, Zonghui et al. (2013) Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208:418-22|
|Graham, Barney S; Enama, Mary E; Nason, Martha C et al. (2013) DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 8:e59340|